Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction — REAGIR  

Acanthamoeba Keratitis Clinical Trial

Official title: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Status Recruiting

Clinical Trial Summary

Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus cross-linking with rose Bengal (RB-PDT). Patients presenting to one of the Aravind Eye Hospitals in India or to the Federal University of São Paulo ophthalmology clinic in Brazil with either smear or culture positive fungal or acanthamoeba keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of two treatment groups: Group 4, Sham RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT Group 5, RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Acanthamoeba Keratitis
• Fungal Keratitis
• Keratitis

• NCT number: NCT05110001
• Study type: Interventional
• Source: University of California, San Francisco
• Contact: Tom Lietman, MD
• Phone: 415-502-2662
• Email: tom.lietman@ucsf.edu
• Status: Recruiting
• Phase: Phase 3
• Start date: August 3, 2022
• Completion date: July 31, 2025